Barclays Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
In a report released today, James Gordon CFA from Barclays maintained a Sell rating on GlaxoSmithKline, with a price target of £19.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Gordon CFA is a 3-star analyst with an average return of 6.9% and a 56.25% success rate. Gordon CFA covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, Galderma Group AG, and Roche Holding AG.
In addition to Barclays, GlaxoSmithKline also received a Sell from J.P. Morgan’s Zain Ebrahim in a report issued yesterday. However, today, Citi maintained a Hold rating on GlaxoSmithKline (LSE: GSK).
Based on GlaxoSmithKline’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p8.62 billion and a net profit of p636 million. In comparison, last year the company earned a revenue of p8.12 billion and had a net profit of p414 million
Based on the recent corporate insider activity of 316 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GSK in relation to earlier this year.
Read More on GB:GSK:
Disclaimer & DisclosureReport an Issue
- GSK Expands Treasury Stock with Latest Share Buyback Tranche
- GSK Executives Reinvest Dividends in Routine Insider Share Purchases
- GSK presents data from its phase I Behold-1 trial for Mo-Rez
- GSK’s B7-H4 Antibody-Drug Conjugate Shows Strong Early Results in Gynaecological Cancers
- GSK Expands Share Buyback, Lifts Treasury Holdings to 6.36% of Voting Rights
